A Fecal MicroRNA Signature by Small RNA Sequencing Accurately
Distinguishes Colorectal Cancers: Results From a Multicenter
Study

J 2023

A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study

PARDINI, Barbara; Giulio FERRERO; Sonia TARALLO; Gaetano GALLO; Antonio FRANCAVILLA et al.

Základní údaje

Originální název

A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study

Autoři

Vydání

Gastroenterology, Philadelphia, W B Saunders co-Elsevier Inc, 2023, 0016-5085

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 26.300

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/23:00132283

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Stool MicroRNAs; Noninvasive Diagnosis; Small RNA Sequencing; Colorectal Cancer; Precancerous Lesions; Machine Learning

Štítky

143180, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 15. 11. 2023 19:26, Mgr. Michaela Hylsová, Ph.D.

Anotace

V originále

BACKGROUND & AIMS: Fecal tests currently used for colorectal cancer (CRC) screening show limited accuracy in detecting early tumors or precancerous lesions. In this respect, we comprehensively evaluated stool microRNA (miRNA) profiles as biomarkers for noninvasive CRC diagnosis. METHODS: A total of 1273 small RNA sequencing experiments were performed in multiple biospecimens. In a cross-sectional study, miRNA profiles were investigated in fecal samples from an Italian and a Czech cohort (155 CRCs, 87 adenomas, 96 other intestinal diseases, 141 colonoscopy-negative controls). A predictive miRNA signature for cancer detection was defined by a machine learning strategy and tested in additional fecal samples from 141 CRC patients and 80 healthy volunteers. miRNA profiles were compared with those of 132 tumors/adenomas paired with adjacent mucosa, 210 plasma extracellular vesicle samples, and 185 fecal immunochemical test leftover samples. RESULTS: Twenty-five miRNAs showed altered levels in the stool of CRC patients in both cohorts (adjusted P < .05). A 5-miRNA signature, including miR-149-3p, miR-607-5p, miR-1246, miR-4488, and miR-6777-5p, distinguished patients from control individuals (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.79-0.94) and was validated in an independent cohort (AUC, 0.96; 95% CI, 0.92-1.00). The signature classified control individuals from patients with low-/high-stage tumors and advanced adenomas (AUC, 0.82; 95% CI, 0.71-0.97). Tissue miRNA profiles mirrored those of stool samples, and fecal profiles of different gastrointestinal diseases highlighted miRNAs specifically dysregulated in CRC. miRNA profiles in fecal immunochemical test leftover samples showed good correlation with those of stool collected in preservative buffer, and their alterations could be detected in adenoma or CRC patients. CONCLUSIONS: Our comprehensive fecal miRNome analysis identified a signature accurately discriminating cancer aimed at improving noninvasive diagnosis and screening strategies.

Návaznosti

EF15_003/0000469, projekt VaV

Název: Cetocoen Plus

EF17_043/0009632, projekt VaV

Název: CETOCOEN Excellence

LM2023069, projekt VaV

Název: Výzkumná infrastruktura RECETOX

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Výzkumná infrastruktura RECETOX

825410, interní kód MU

Název: Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response (Akronym: ONCOBIOME)

Investor: Evropská unie, Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response, Health, demographic change and wellbeing (Societal Challenges)

Přiložené soubory

2339761.pdf

Citovat

PARDINI, Barbara; Giulio FERRERO; Sonia TARALLO; Gaetano GALLO; Antonio FRANCAVILLA; Nicola LICHERI; Mario TROMPETTO; Giuseppe CLERICO; Carlo SENORE; Sergio PEYRE; Veronika VYMETALKOVA; Ludmila VODICKOVA; Vaclav LISKA; Ondrej VYCITAL; Miroslav LEVY; Peter MACINGA; Tomas HUCL; Eva BUDINSKÁ; Pavel VODICKA; Francesca CORDERO a Alessio NACCARATI. A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study. Gastroenterology. Philadelphia: W B Saunders co-Elsevier Inc, 2023, roč. 165, č. 3, s. 582-607. ISSN 0016-5085. Dostupné z: https://doi.org/10.1053/j.gastro.2023.05.037.

@article{2339761,
   author = {Pardini, Barbara and Ferrero, Giulio and Tarallo, Sonia and Gallo, Gaetano and Francavilla, Antonio and Licheri, Nicola and Trompetto, Mario and Clerico, Giuseppe and Senore, Carlo and Peyre, Sergio and Vymetalkova, Veronika and Vodickova, Ludmila and Liska, Vaclav and Vycital, Ondrej and Levy, Miroslav and Macinga, Peter and Hucl, Tomas and Budinská, Eva and Vodicka, Pavel and Cordero, Francesca and Naccarati, Alessio},
   article_location = {Philadelphia},
   article_number = {3},
   doi = {https://doi.org/10.1053/j.gastro.2023.05.037},
   keywords = {Stool MicroRNAs; Noninvasive Diagnosis; Small RNA Sequencing; Colorectal Cancer; Precancerous Lesions; Machine Learning},
   language = {eng},
   issn = {0016-5085},
   journal = {Gastroenterology},
   title = {A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study},
   url = {https://www.sciencedirect.com/science/article/pii/S0016508523008119?via%3Dihub},
   volume = {165},
   year = {2023}
}

TY  - JOUR
ID  - 2339761
AU  - Pardini, Barbara - Ferrero, Giulio - Tarallo, Sonia - Gallo, Gaetano - Francavilla, Antonio - Licheri, Nicola - Trompetto, Mario - Clerico, Giuseppe - Senore, Carlo - Peyre, Sergio - Vymetalkova, Veronika - Vodickova, Ludmila - Liska, Vaclav - Vycital, Ondrej - Levy, Miroslav - Macinga, Peter - Hucl, Tomas - Budinská, Eva - Vodicka, Pavel - Cordero, Francesca - Naccarati, Alessio
PY  - 2023
TI  - A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study
JF  - Gastroenterology
VL  - 165
IS  - 3
SP  - 582-607
EP  - 582-607
PB  - W B Saunders co-Elsevier Inc
SN  - 00165085
KW  - Stool MicroRNAs
KW  - Noninvasive Diagnosis
KW  - Small RNA Sequencing
KW  - Colorectal Cancer
KW  - Precancerous Lesions
KW  - Machine Learning
UR  - https://www.sciencedirect.com/science/article/pii/S0016508523008119?via%3Dihub
N2  - BACKGROUND & AIMS: Fecal tests currently used for colorectal cancer (CRC) screening show limited accuracy in detecting early tumors or precancerous lesions. In this respect, we comprehensively evaluated stool microRNA (miRNA) profiles as biomarkers for noninvasive CRC diagnosis. METHODS: A total of 1273 small RNA sequencing experiments were performed in multiple biospecimens. In a cross-sectional study, miRNA profiles were investigated in fecal samples from an Italian and a Czech cohort (155 CRCs, 87 adenomas, 96 other intestinal diseases, 141 colonoscopy-negative controls). A predictive miRNA signature for cancer detection was defined by a machine learning strategy and tested in additional fecal samples from 141 CRC patients and 80 healthy volunteers. miRNA profiles were compared with those of 132 tumors/adenomas paired with adjacent mucosa, 210 plasma extracellular vesicle samples, and 185 fecal immunochemical test leftover samples. RESULTS: Twenty-five miRNAs showed altered levels in the stool of CRC patients in both cohorts (adjusted P < .05). A 5-miRNA signature, including miR-149-3p, miR-607-5p, miR-1246, miR-4488, and miR-6777-5p, distinguished patients from control individuals (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.79-0.94) and was validated in an independent cohort (AUC, 0.96; 95% CI, 0.92-1.00). The signature classified control individuals from patients with low-/high-stage tumors and advanced adenomas (AUC, 0.82; 95% CI, 0.71-0.97). Tissue miRNA profiles mirrored those of stool samples, and fecal profiles of different gastrointestinal diseases highlighted miRNAs specifically dysregulated in CRC. miRNA profiles in fecal immunochemical test leftover samples showed good correlation with those of stool collected in preservative buffer, and their alterations could be detected in adenoma or CRC patients. CONCLUSIONS: Our comprehensive fecal miRNome analysis identified a signature accurately discriminating cancer aimed at improving noninvasive diagnosis and screening strategies.
ER  -

PARDINI, Barbara; Giulio FERRERO; Sonia TARALLO; Gaetano GALLO; Antonio FRANCAVILLA; Nicola LICHERI; Mario TROMPETTO; Giuseppe CLERICO; Carlo SENORE; Sergio PEYRE; Veronika VYMETALKOVA; Ludmila VODICKOVA; Vaclav LISKA; Ondrej VYCITAL; Miroslav LEVY; Peter MACINGA; Tomas HUCL; Eva BUDINSKÁ; Pavel VODICKA; Francesca CORDERO a Alessio NACCARATI. A Fecal MicroRNA Signature by Small RNA Sequencing Accurately Distinguishes Colorectal Cancers: Results From a Multicenter Study. \textit{Gastroenterology}. Philadelphia: W B Saunders co-Elsevier Inc, 2023, roč.~165, č.~3, s.~582-607. ISSN~0016-5085. Dostupné z: https://doi.org/10.1053/j.gastro.2023.05.037.

Přehled o publikaci